| Category | 2019 2H |
2020 1H |
2020 2H |
2021 1H |
2021 2H |
Target indication | |
|---|---|---|---|---|---|---|---|
| OPTA-INFLA | |||||||
| Acute inflammatory disease |
IV |
Process dev.
|
PK & Tox
|
Non-Clinical Stage
|
IRI, transplantation, GvHD, or others | ||
| Chronic inflammatory disease |
SC |
PK, Tox & Efficacy profiling
|
Process dev.
|
COPD, MS, or others | |||
| Oral |
Process dev.
|
IBD | |||||
| OPTA-ONCO | |||||||
| Drug delivery system | IV |
Process dev.
|
Process dev.
|
Cancer drug carrier | |||
| Discovery projects | |||||||
| Discovery projects |
Discovery
|
TBD | |||||
2020-05-25